[
  {
    "ts": null,
    "headline": "Schwab’s SCHD ETF Is Mostly Solid, But 1 Top Holding Is Concerning",
    "summary": "The Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) is a popular income choice for retirees. The fund generates income by holding a portfolio of dividend-paying U.S. stocks selected for their financial strength and dividend consistency. The ETF tracks the Dow Jones U.S. Dividend 100 Index, which screens for companies with at least 10 consecutive years of ... Schwab’s SCHD ETF Is Mostly Solid, But 1 Top Holding Is Concerning",
    "url": "https://finnhub.io/api/news?id=9fc128ffa1bd92857548e11b9282c0e28873d4b5dcefbf9463a7e3226b50f9d3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765324388,
      "headline": "Schwab’s SCHD ETF Is Mostly Solid, But 1 Top Holding Is Concerning",
      "id": 137749929,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) is a popular income choice for retirees. The fund generates income by holding a portfolio of dividend-paying U.S. stocks selected for their financial strength and dividend consistency. The ETF tracks the Dow Jones U.S. Dividend 100 Index, which screens for companies with at least 10 consecutive years of ... Schwab’s SCHD ETF Is Mostly Solid, But 1 Top Holding Is Concerning",
      "url": "https://finnhub.io/api/news?id=9fc128ffa1bd92857548e11b9282c0e28873d4b5dcefbf9463a7e3226b50f9d3"
    }
  },
  {
    "ts": null,
    "headline": "Pharma ETFs to Gain From Landmark UK-US Zero-Tariff Deal",
    "summary": "Pharma ETFs like IHE are poised to surge as the UK-US zero-tariff deal raises UK drug prices and strengthens major U.S. players' outlook.",
    "url": "https://finnhub.io/api/news?id=18c6c518fd9ae16d7e56818f8e62791ae026a9ff69d57b0ee4933283232cc6a8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765305600,
      "headline": "Pharma ETFs to Gain From Landmark UK-US Zero-Tariff Deal",
      "id": 137749832,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Pharma ETFs like IHE are poised to surge as the UK-US zero-tariff deal raises UK drug prices and strengthens major U.S. players' outlook.",
      "url": "https://finnhub.io/api/news?id=18c6c518fd9ae16d7e56818f8e62791ae026a9ff69d57b0ee4933283232cc6a8"
    }
  },
  {
    "ts": null,
    "headline": "BioNTech: Maintaining \"Strong Buy\" After Part 1 Success Of Next-Gen Anti-CTLA-4 Gotistobart",
    "summary": "BioNTech stock is a \"Strong Buy\", driven by positive phase 3 data for gotistobart in 2nd-line squamous NSCLC patients. Read the full analysis here.",
    "url": "https://finnhub.io/api/news?id=5783584119cffb601eb58492ea4e972340515254eace6399b29cbe2e717b3bc0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765302863,
      "headline": "BioNTech: Maintaining \"Strong Buy\" After Part 1 Success Of Next-Gen Anti-CTLA-4 Gotistobart",
      "id": 137743809,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2242604824/image_2242604824.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "BioNTech stock is a \"Strong Buy\", driven by positive phase 3 data for gotistobart in 2nd-line squamous NSCLC patients. Read the full analysis here.",
      "url": "https://finnhub.io/api/news?id=5783584119cffb601eb58492ea4e972340515254eace6399b29cbe2e717b3bc0"
    }
  },
  {
    "ts": null,
    "headline": "Here's 1 Major Catalyst Behind Merck Stock's Recent 3.8% Bump",
    "summary": "The company is finding ways to overcome the headwinds it will encounter in the medium term.",
    "url": "https://finnhub.io/api/news?id=96834f28daf1ef058a1732def552d022c795053591a0ef845b7d0662dcf7b8b8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765298100,
      "headline": "Here's 1 Major Catalyst Behind Merck Stock's Recent 3.8% Bump",
      "id": 137742690,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The company is finding ways to overcome the headwinds it will encounter in the medium term.",
      "url": "https://finnhub.io/api/news?id=96834f28daf1ef058a1732def552d022c795053591a0ef845b7d0662dcf7b8b8"
    }
  },
  {
    "ts": null,
    "headline": "1 Major Factor Behind the Healthcare Sector's Recent Surge",
    "summary": "Blockbuster drugs are a major driver of the growth of healthcare stocks.",
    "url": "https://finnhub.io/api/news?id=961fc079ac660d5adfeab69920ace9a1d553cc860668ba87c4183f0a08ab4342",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765296917,
      "headline": "1 Major Factor Behind the Healthcare Sector's Recent Surge",
      "id": 137741749,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Blockbuster drugs are a major driver of the growth of healthcare stocks.",
      "url": "https://finnhub.io/api/news?id=961fc079ac660d5adfeab69920ace9a1d553cc860668ba87c4183f0a08ab4342"
    }
  },
  {
    "ts": null,
    "headline": "MRK Stock Trading Above 200- & 50-Day SMA for 2 Months: Time to Buy?",
    "summary": "Merck holds bullish momentum as pipeline advances and major deals offset vaccine weakness and Keytruda risks.",
    "url": "https://finnhub.io/api/news?id=04cb8253f5c8fe8c2e9373525a2d0fc1479f1decd459935c45d45472460a7f91",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765296240,
      "headline": "MRK Stock Trading Above 200- & 50-Day SMA for 2 Months: Time to Buy?",
      "id": 137742693,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck holds bullish momentum as pipeline advances and major deals offset vaccine weakness and Keytruda risks.",
      "url": "https://finnhub.io/api/news?id=04cb8253f5c8fe8c2e9373525a2d0fc1479f1decd459935c45d45472460a7f91"
    }
  },
  {
    "ts": null,
    "headline": "Global Market for Merkel Cell Carcinoma Driven by Key Players Like Merck & Bristol Myers Squibb",
    "summary": "The global Merkel Cell Carcinoma (MCC) market is rapidly evolving, driven by advancements in immunotherapy and a surge in early diagnoses. Merkel cell carcinoma, a rare, aggressive skin cancer mainly affecting older adults, is increasingly being treated with immune checkpoint inhibitors like Keytruda and Opdivo, which have revolutionized patient survival rates. The market faces challenges with the high cost of treatments impacting accessibility. Key players such as Merck, Bristol Myers Squibb, a",
    "url": "https://finnhub.io/api/news?id=96338e445ef0d15113a47f0fd5daf51bbc8e1ebf5744e5557f3cc8964b1e7c2d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765292280,
      "headline": "Global Market for Merkel Cell Carcinoma Driven by Key Players Like Merck & Bristol Myers Squibb",
      "id": 137742694,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The global Merkel Cell Carcinoma (MCC) market is rapidly evolving, driven by advancements in immunotherapy and a surge in early diagnoses. Merkel cell carcinoma, a rare, aggressive skin cancer mainly affecting older adults, is increasingly being treated with immune checkpoint inhibitors like Keytruda and Opdivo, which have revolutionized patient survival rates. The market faces challenges with the high cost of treatments impacting accessibility. Key players such as Merck, Bristol Myers Squibb, a",
      "url": "https://finnhub.io/api/news?id=96338e445ef0d15113a47f0fd5daf51bbc8e1ebf5744e5557f3cc8964b1e7c2d"
    }
  },
  {
    "ts": null,
    "headline": "BenchSci Extends ASCEND Agreement with Merck to Support Preclinical Disease Biology Research",
    "summary": "TORONTO, December 09, 2025--BenchSci, a leading provider of AI software for biopharma research and development, today announced a renewed two-year contract with Merck, known as MSD outside of the United States and Canada.",
    "url": "https://finnhub.io/api/news?id=ec7e98f8bfc8ab494c832d5023fa8f0c4cfe9ccb2d4cd16cbb8ca704afc66043",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765285200,
      "headline": "BenchSci Extends ASCEND Agreement with Merck to Support Preclinical Disease Biology Research",
      "id": 137740188,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "TORONTO, December 09, 2025--BenchSci, a leading provider of AI software for biopharma research and development, today announced a renewed two-year contract with Merck, known as MSD outside of the United States and Canada.",
      "url": "https://finnhub.io/api/news?id=ec7e98f8bfc8ab494c832d5023fa8f0c4cfe9ccb2d4cd16cbb8ca704afc66043"
    }
  },
  {
    "ts": null,
    "headline": "Ability Biotherapeutics Appoints Angèle Maki, PhD, as Chief Business Officer",
    "summary": "MONTREAL, December 09, 2025--Ability Biotherapeutics, a biotechnology company advancing logic-gated antibody therapies for cancer and autoimmune diseases, today announced the appointment of Angèle Maki, PhD, as Chief Business Officer (CBO).",
    "url": "https://finnhub.io/api/news?id=a7e4d9343a9e5f5495c6c8ca3af18095dc62604cf691f2f06bb802cc1da57cb5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765284300,
      "headline": "Ability Biotherapeutics Appoints Angèle Maki, PhD, as Chief Business Officer",
      "id": 137740091,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "MONTREAL, December 09, 2025--Ability Biotherapeutics, a biotechnology company advancing logic-gated antibody therapies for cancer and autoimmune diseases, today announced the appointment of Angèle Maki, PhD, as Chief Business Officer (CBO).",
      "url": "https://finnhub.io/api/news?id=a7e4d9343a9e5f5495c6c8ca3af18095dc62604cf691f2f06bb802cc1da57cb5"
    }
  },
  {
    "ts": null,
    "headline": "How Protein And Pets Drove Elanco Animal Health's 79% Gain In 2025",
    "summary": "Elanco Animal Health CEO Jeff Simmons says the company is in the best position it's been in years. Elanco stock has surged in 2025.",
    "url": "https://finnhub.io/api/news?id=8483b90c2d6aadc206d0635b2c5c21899f968c7d4785c76e22a89756057ee41e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765284036,
      "headline": "How Protein And Pets Drove Elanco Animal Health's 79% Gain In 2025",
      "id": 137740190,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Elanco Animal Health CEO Jeff Simmons says the company is in the best position it's been in years. Elanco stock has surged in 2025.",
      "url": "https://finnhub.io/api/news?id=8483b90c2d6aadc206d0635b2c5c21899f968c7d4785c76e22a89756057ee41e"
    }
  },
  {
    "ts": null,
    "headline": "FDA approves Merck drug for decimated U.S. cattle herds to stop screwworm",
    "summary": "There's hope for U.S. cattle ranchers in the battle to stop the spread of screwworm at a time of decimated herds with the FDA approving a new Merck treatment.",
    "url": "https://finnhub.io/api/news?id=b0ada9ccd5b497699183574d80e6b4c39d9715ec01bcdbe9b9d6ee046bec363e",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765281081,
      "headline": "FDA approves Merck drug for decimated U.S. cattle herds to stop screwworm",
      "id": 137741838,
      "image": "https://image.cnbcfm.com/api/v1/image/108214613-1761046870334-gettyimages-2186604010-AA_28112024_1963338.jpeg?v=1761046913&w=1920&h=1080",
      "related": "MRK",
      "source": "CNBC",
      "summary": "There's hope for U.S. cattle ranchers in the battle to stop the spread of screwworm at a time of decimated herds with the FDA approving a new Merck treatment.",
      "url": "https://finnhub.io/api/news?id=b0ada9ccd5b497699183574d80e6b4c39d9715ec01bcdbe9b9d6ee046bec363e"
    }
  },
  {
    "ts": null,
    "headline": "Strategic Pharma Collaborations Propel RCC Market Growth",
    "summary": "The global advanced renal cell carcinoma (RCC) market is experiencing rapid growth driven by innovative treatment approaches, rising disease awareness, and an expanding patient base. Key factors include the adoption of targeted therapies and immunotherapies, personalized medicine, and strategic collaborations among industry leaders such as Pfizer, Merck & Co., and AstraZeneca.Dublin, Dec. 09, 2025 (GLOBE NEWSWIRE) -- The \"Advanced Renal Cell Carcinoma (RCC) Market - A Global and Regional Analysi",
    "url": "https://finnhub.io/api/news?id=6e04a3b15082455c2494b7f8a2365f33615f168f67ba566f3eeb4b7fad3c09db",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765276020,
      "headline": "Strategic Pharma Collaborations Propel RCC Market Growth",
      "id": 137740191,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The global advanced renal cell carcinoma (RCC) market is experiencing rapid growth driven by innovative treatment approaches, rising disease awareness, and an expanding patient base. Key factors include the adoption of targeted therapies and immunotherapies, personalized medicine, and strategic collaborations among industry leaders such as Pfizer, Merck & Co., and AstraZeneca.Dublin, Dec. 09, 2025 (GLOBE NEWSWIRE) -- The \"Advanced Renal Cell Carcinoma (RCC) Market - A Global and Regional Analysi",
      "url": "https://finnhub.io/api/news?id=6e04a3b15082455c2494b7f8a2365f33615f168f67ba566f3eeb4b7fad3c09db"
    }
  },
  {
    "ts": null,
    "headline": "Moat Stocks Gain On Health Care Strength, Tech Slowdown",
    "summary": "Moat Index gained 1.53% in November, supported by health care and broader market participation.\nMerck and Amgen were top Moat Index contributors, benefiting from strong demand and pipelines.",
    "url": "https://finnhub.io/api/news?id=2ea8abce7d23f3dd04e56d1e25e81f5ded986f8c0fd4f22e4f8ff4587ef88700",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765257960,
      "headline": "Moat Stocks Gain On Health Care Strength, Tech Slowdown",
      "id": 137738946,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/976507484/image_976507484.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Moat Index gained 1.53% in November, supported by health care and broader market participation.\nMerck and Amgen were top Moat Index contributors, benefiting from strong demand and pipelines.",
      "url": "https://finnhub.io/api/news?id=2ea8abce7d23f3dd04e56d1e25e81f5ded986f8c0fd4f22e4f8ff4587ef88700"
    }
  },
  {
    "ts": null,
    "headline": "These 2 High-Yield Dividend Stocks Are Some of the Safest Buys Right Now",
    "summary": "Merck and Duke Energy stand out as rare “safe yield” plays, pairing 3%+ dividends with solid earnings growth, reasonable payout ratios, and durable demand drivers in healthcare and regulated utilities.",
    "url": "https://finnhub.io/api/news?id=3bbdd87f28c97f7cfbed8f3fdfa2bbcae6ac6a30e3e29f45e53f7b0aba4eb7ef",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765240202,
      "headline": "These 2 High-Yield Dividend Stocks Are Some of the Safest Buys Right Now",
      "id": 137737854,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck and Duke Energy stand out as rare “safe yield” plays, pairing 3%+ dividends with solid earnings growth, reasonable payout ratios, and durable demand drivers in healthcare and regulated utilities.",
      "url": "https://finnhub.io/api/news?id=3bbdd87f28c97f7cfbed8f3fdfa2bbcae6ac6a30e3e29f45e53f7b0aba4eb7ef"
    }
  }
]